BioLife Solutions
BLFS Nasdaq· Health Care Supplies
KIRA · Stoqly’s AI analyst, in plain words
- BioLife Solutions had $96.2M of revenue in fiscal 2025, up 28.9% on the year before. Over five years, revenue changed +14.9% a year on average.
- Its operating margin was −17.3%, down 11.3 pts: of every 100 in sales, about −17 is left after running the business.
- BioLife Solutions lost $4.6M in fiscal 2025.
- Free cash flow was $10.6M in fiscal 2025, 11.1% of revenue.
- BioLife Solutions returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 5.6%.
- BioLife Solutions has $83.9M more cash than debt.
Market cap
—
P/E
—
Revenue
$96.2M
Net income
−$4.6M
Free cash flow
$10.6M
Operating margin
−17.3%
BioLife Solutions in 30 seconds · fiscal 2025
Are sales growing?
+28.9%
Yes. Sales grew 28.9% last year.
Does it make a profit?
−4.8%
No. It lost money last year.
Does profit turn into cash?
11.1%
Yes. 11.1% of sales ends up as free cash.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
What BioLife Solutions does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- BioLife Solutions, Inc.
- CIK
- 0000834365
BioLife Solutions · BLFS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $119M | $76.2M | $68.0M | $74.6M | $96.2M |
| Revenue growth | 147.8% | −36.0% | −10.8% | 9.8% | 28.9% |
| Gross margin | — | — | 60.8% | 67.1% | 64.6% |
| Operating margin | −29.5% | −7.8% | −25.3% | −6.0% | −17.3% |
| Net income | −$8.9M | −$140M | −$68.0M | −$20.2M | −$4.6M |
| Net margin | −7.5% | −183.4% | −100.0% | −27.0% | −4.8% |
| Diluted EPS | −$0.23 | −$3.25 | −$1.55 | −$0.44 | −$0.10 |
| Cash | |||||
| Cash from operations | −$4.6M | −$8.5M | −$12.5M | $8.4M | $20.1M |
| Capital expenditure | $8.4M | $10.4M | $6.4M | $3.2M | $9.5M |
| Free cash flow | −$13.0M | −$18.9M | −$18.9M | $5.2M | $10.6M |
| FCF margin | −10.9% | −24.8% | −27.8% | 7.0% | 11.1% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 41.0% | 11.9% | 1.5% | 5.4% | 5.6% |
| Debt and strength | |||||
| Cash and short-term investments | $69.9M | $62.7M | $44.2M | $101M | $88.9M |
| Debt incl. finance leases | $7.7M | $25.9M | $25.4M | $15.9M | $5.0M |
| Shareholders' equity | $478M | $364M | $338M | $349M | $372M |
| Net debt / EBITDA | — | −43.2x | — | −124.2x | — |
| Current ratio | 3.0x | 3.1x | 2.9x | 4.5x | 5.9x |
| Interest coverage | −77.8x | −10.1x | −8.9x | −2.8x | −21.8x |
| Returns and quality | |||||
| Return on capital | −10.5% | −1.3% | −4.2% | −1.2% | −4.8% |
| Return on equity | −2.6% | −33.2% | −19.4% | −5.9% | −1.3% |
| Piotroski F-score | 1 | 2 | 3 | 7 | 6 |
| Altman Z'' | 6.5 | 3.9 | 3.2 | 6.3 | 10.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$34.0M
9 insiders
Of sales under plans
1%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BioLife Solutions · BLFS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| BioLife Solutions BLFS | — | 28.9% | −17.3% | 11.1% | −4.8% | — | 6 |
| Haemonetics HAE | $5.4B | −2.0% | 11.8% | 19.5% | 6.7% | 57.6x | 7 |
| Lantheus LNTH | $6.7B | 0.5% | 20.2% | 23.0% | 22.7% | 24.2x | 5 |
| ICU Medical ICUI | $4.1B | −6.3% | 1.9% | 4.1% | 0.7% | 139.5x | 6 |
| Envista NVST | $3.9B | 8.3% | 8.0% | 8.5% | 3.2% | 40.8x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
BioLife Solutions grew sales faster than 4 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0000834365). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.